MAGNA Stock Overview
A diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Magnasense AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.35 |
52 Week High | SEK 1.66 |
52 Week Low | SEK 0.33 |
Beta | 2.75 |
11 Month Change | -18.60% |
3 Month Change | -27.16% |
1 Year Change | -76.17% |
33 Year Change | -99.91% |
5 Year Change | n/a |
Change since IPO | -96.67% |
Recent News & Updates
Recent updates
Shareholder Returns
MAGNA | SE Biotechs | SE Market | |
---|---|---|---|
7D | -14.4% | -5.4% | -4.2% |
1Y | -76.2% | 18.1% | 12.5% |
Return vs Industry: MAGNA underperformed the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: MAGNA underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
MAGNA volatility | |
---|---|
MAGNA Average Weekly Movement | 14.5% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: MAGNA's share price has been volatile over the past 3 months.
Volatility Over Time: MAGNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 14 | Marco Wititteveen | www.magnasense.com |
Magnasense AB, a diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally. The company focuses on the neurology, oncology, and autoimmune therapeutic areas. It offers moNATor, a first dose-monitoring laboratory test that provides multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit.
Magnasense AB Fundamentals Summary
MAGNA fundamental statistics | |
---|---|
Market cap | SEK 12.62m |
Earnings (TTM) | -SEK 49.38m |
Revenue (TTM) | SEK 36.00k |
350.5x
P/S Ratio-0.3x
P/E RatioIs MAGNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MAGNA income statement (TTM) | |
---|---|
Revenue | SEK 36.00k |
Cost of Revenue | -SEK 92.00k |
Gross Profit | SEK 128.00k |
Other Expenses | SEK 49.50m |
Earnings | -SEK 49.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.37 |
Gross Margin | 355.56% |
Net Profit Margin | -137,155.56% |
Debt/Equity Ratio | -340.0% |
How did MAGNA perform over the long term?
See historical performance and comparison